Maze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at Citigroup

Maze Therapeutics (NASDAQ:MAZE) was upgraded by research analysts at Citigroup to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

MAZE has been the topic of a number of other research reports. BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Price Performance

MAZE opened at $26.21 on Wednesday. The firm has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The stock has a 50-day moving average price of $27.16 and a 200-day moving average price of $29.04. Maze Therapeutics has a 1 year low of $21.95 and a 1 year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Sell-side analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the sale, the insider directly owned 7,007 shares in the company, valued at $182,252.07. The trade was a 22.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason V. Coloma sold 11,411 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the sale, the chief executive officer owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. This represents a 29.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 191,459 shares of company stock worth $5,263,539 in the last three months. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in MAZE. Frazier Life Sciences Management L.P. boosted its holdings in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the last quarter. TRV GP IV LLC purchased a new stake in Maze Therapeutics during the second quarter valued at approximately $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics in the second quarter worth approximately $122,983,582. BlackRock Inc. purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth $104,525,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Maze Therapeutics in the 2nd quarter worth $101,764,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: New buy ratings support the investment case. Citigroup and BTIG both initiated coverage with Buy ratings and $50 price targets, implying substantial upside from the recent $26.21 reference price. Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
• Positive Sentiment: Existing analysts remain bullish. HC Wainwright reaffirmed its Buy rating and $110 target, while Wedbush maintained an Outperform rating with a $48 target. These targets reflect analysts’ confidence in Maze’s pipeline, although they also indicate considerable execution risk for a clinical-stage biotechnology company. HC Wainwright Reaffirms Maze Therapeutics Buy Rating
• Positive Sentiment: Recent coverage has generated investor interest. Shares rose 2.9% after CIBC initiated coverage, indicating that new brokerage coverage can provide short-term support for MAZE. Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
• Neutral Sentiment: Reported short interest is zero shares. The September 24 report lists no short positions and a 0.0-day short-interest ratio. This removes evidence of meaningful short-selling pressure or squeeze potential, though the figure may reflect a reporting or data anomaly rather than a fundamental change.
• Neutral Sentiment: Sector news is supportive but indirect. Strong results for a rival kidney-drug developer may reinforce interest in the biotechnology and renal-disease markets, but the development does not directly change Maze’s financial results or clinical outlook. Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.